Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | FLT4 | P35916 | 5/20 | 0.46 |
| ▸ | FLT3 | P36888 | 5/20 | 0.46 |
| ▸ | PLK4 | O00444 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364499 | 0.86 | PDGFRB (0.44) | PDGFRBPDGFRACYP2A6IMPDH2MAPT | |
| SCHEMBL229716 | 0.75 | EZH2 (0.59) | PDGFRBKDRFLT3AURKAAURKB | |
| SCHEMBL7149485 | 0.72 | CYP2A6 (0.50) | PDGFRBKDRFLT4FLT3PLK4 | |
| SCHEMBL31213227 | 0.71 | KDR (0.49) | PDGFRBKDRFLT4FLT3PLK4 | |
| SCHEMBL27494000 | 0.70 | PDGFRB (0.51) | PDGFRBKDRFLT4FLT3PLK4 | |
| SCHEMBL17179277 | 0.69 | ITK (0.60) | PDGFRBKDRFLT3AURKAPDGFRA | |
| SCHEMBL4329785 | 0.69 | KDR (0.70) | PDGFRBKDRFLT4FLT3PLK4 | |
| SCHEMBL1899742 | 0.68 | SLC22A6 (0.59) | PDGFRBPDGFRATUBB4ATUBBTUBA3C | |
| SCHEMBL2476987 | 0.67 | CHEK1 (0.54) | PDGFRBKDRPDGFRACDK4CCND1 | |
| SCHEMBL26634479 | 0.67 | TUBB1 (0.64) | PDGFRBKDRFLT4FLT3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.) | 2012-01-05 | — | — | US | disclosed |
| US-7709477-B2 | Methods for treating cancer | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| EP-1853255-A4 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | GEMIN X PHARMACEUTICALS CANADA (CA) | 2009-07-08 | — | — | EP | disclosed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-7425553-B2 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-09-16 | — | — | US | disclosed |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-03-27 | — | — | US | disclosed |
| EP-1853255-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | Gemin X Biotechnologies Inc. (CA) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089397-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2006-08-31 | — | — | WO | disclosed |
| EP-1644363-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | Gemin X Biotechnologies Inc. (CA) | 2006-04-12 | — | — | EP | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| WO-2005117908-A2 | TRIHETEROCYCLIC COMPOUNDS COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES, INC. (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2005-12-01 | — | — | US | disclosed |
| US-20050014802-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004106328-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | PDGFRB 2972/4885KDR 3293/4885FLT4 2472/4885 |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | HCAR2, TNF, CD38 | PDGFRB 3350/4885KDR 4196/4885FLT4 2947/4885 |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | ZC3HAV1, HCCS, PCNA | PDGFRB 2992/4885KDR 2590/4885FLT4 2364/4885 |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | PDGFRB 3191/4885KDR 2644/4885FLT4 2676/4885 |
| US-20050014802-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | PDGFRB 3191/4885KDR 2644/4885FLT4 2676/4885 |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | ZC3HAV1, HCCS, PCNA | PDGFRB 2992/4885KDR 2590/4885FLT4 2364/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | PDGFRB 3191/4885KDR 2644/4885FLT4 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.